功能支循环氧化酶-2:在老鼠和人类中不对称的二甲基氨基酸轴
Plinio Ferreira1, Ricky Vaja1, Maria Lopes-Pires1
1National Heart and Lung Institute, Imperial College London, United Kingdom.
Kidney international reports
|June 7, 2023
概括
降低循环氧化酶-2 (COX-2) 或前环素的功能会增加不对称的二甲基氨基 (ADMA),并损害功能. 恢复COX-2/prostacyclin信号传递可以改善功能,降低ADMA水平.
科学领域:
- 心血管生理学心血管生理学
- 生物标志物研究的研究.
- 在前列腺中发出信号.
背景情况:
- 循环氧化酶-2 (COX-2) 产生前环素,这对于心脏脏保护至关重要.
- 非对称二甲基氨基 (ADMA) 是心血管和脏疾病的关键生物标志物.
- 需要进一步阐明COX-2/prostacyclin,ADMA和功能之间的相互作用.
研究的目的:
- 在小鼠和人类模型中研究COX-2/前环素信号传导,ADMA水平和功能之间的关系.
- 为了确定受损的COX-2/prostacyclin通路如何影响ADMA和功能.
主要方法:
- 使用了来自COX-2或前环素合成酶淘汰小鼠的血.
- 在移植前和之后,分析了来自单一患者的样本,该患者在细胞质脂酶A2 (cPLA2) 中发生了功能丧失突变,影响了前列腺素的产生.
- 使用超高性能液体染色学-双重质谱法和ELISA测量了ADMA,氨酸,氨酸和氨酸C.
主要成果:
- 在小鼠中,COX-2或前环素合成酶的损失导致血ADMA,,氨酸和氨酸的增加.
- 与健康的志愿者相比,该患者的ADMA,素和囊素C水平升高.
- 成功的移植使患者的功能,ADMA和素水平正常化.
结论:
- 由于COX-2/prostacyclin信号丧失而导致的功能受损与人类和小鼠模型中的ADMA水平升高有关.
- 恢复COX-2/前环素活性可以改善功能,并降低ADMA水平.
关键词:
ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA ADMA was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was that was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was that was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was这是NSAID.脏 脏 脏是什么?氧化氧化的使用方法简介:前环素是一种前环素.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
470
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
470
01:28Glomerular Filtration Rate and its Regulation
3.0K
The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
3.0K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
703
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
703
01:25Antihypertensive Drugs: Direct Renin Inhibitors
711
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
711